EGFR and breast cancer: Researchers have shown efficient cellular and nuclear uptake of 111In-labeled anti-EGFR immunoconjugates with and without NLS-conjugation, which resulted in effective cell kill and localization at the tumor site as visualized by SPECT in EGFR-overexpressing breast cancer MDA-MB-468 xenografts (Fasih et al., 2012).